Joseph C. Papa - 11 Jul 2025 Form 4 Insider Report for Milestone Pharmaceuticals Inc. (MIST)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
15 Jul 2025, 16:15:07 UTC
Prior SEC filing
26 Jun 2025
Next SEC filing
05 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jason Minio, Attorney-in-Fact

Key filing fact

Joseph C. Papa filed Form 4 for Milestone Pharmaceuticals Inc. (MIST) on 15 Jul 2025.

Key facts

  • This page summarizes Joseph C. Papa's Form 4 filing for Milestone Pharmaceuticals Inc. (MIST).
  • 3 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 15 Jul 2025, 16:15.

Change

  • Previous filing in this sequence was filed on 26 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001242215 Primary reporting owner

PAPA JOSEPH C

Relationship
Director
Address
C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, QUEBEC, CANADA
Signature
/s/ Jason Minio, Attorney-in-Fact
Signature date
15 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIST transaction

Common Shares

Award

Transaction value
Shares
+100,000
Change %
Price
Shares after
100,000
Date
11 Jul 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIST transaction Derivative

Series A Common Warrants (right to buy)

Award

Transaction value
Shares
+100,000
Change %
Price
Shares after
100,000
Date
11 Jul 2025
Ownership
Direct
Underlying class
Common Shares
Underlying amount
100,000
Exercise price
$1.50
Footnotes
F1, F2
MIST transaction Derivative

Series B Common Warrants (right to buy)

Award

Transaction value
Shares
+100,000
Change %
Price
Shares after
100,000
Date
11 Jul 2025
Ownership
Direct
Underlying class
Common Shares
Underlying amount
100,000
Exercise price
$1.88
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reported securities are included within 100,000 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 100,000 shares of common stock.

Footnote F2

Fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .